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Proliferative vitreoretinopathy (PVR) is a vision-threatening disease and a common complication of surgery to correct
rhegmatogenous retinal detachment (RRD). Several models of the pathogenesis of this disease have been described with some
of these models focusing on the role of inﬂammatory cells and other models focusing on the role of growth factors and cytokines
in the vitreous which come into contact with intraretinal and retinal pigment epithelial cells. New experiments have shed light
on the pathogenesis of PVR and oﬀer promising avenues for clinical intervention before PVR develops. One such target is the
indirect pathway of activation of platelet-derived growth factor receptor alpha (PDGRα), which plays an important role in PVR.
Clinical trials assessing the eﬃcacy of 5-ﬂuorouracil (5-FU) and low-molecular-weight heparin (LMWH), daunorubicin, and 13-
cis-retinoic acid, among other therapies, have yielded mixed results. Here we review inﬂammatory and other mechanisms involved
in the pathogenesis of PVR, we highlight important clinical trials, and we discuss how ﬁndings at the bench have the potential to
be translated to the bedside.
1.Introduction
Proliferative vitreoretinopathy (PVR) is a vision-threatening
diseasethatcanoccursecondarytoretinaldetachment(RD).
RD allows macrophages, retinal pigment epithelial (RPE)
cells, glial cells, and ﬁbroblasts to migrate to the vitreous,
where they proliferate, survive, form extracellular matrix
proteins and assemble into a membrane [1]. This membrane
can attach to the retina and subsequently contract, which
can cause a new retinal detachment or failure of a surgically
corrected detachment [2] .P V Ro c c u r sm o s tc o m m o n l ya sa
complication of surgery to correct rhegmatogenous retinal
detachment (RRD) and is the most common reason for the
failure of this operation [3, 4]. In one study of 119 patients
with RRD and no previous vitreoretinal surgery, there was
a 52.9% prevalence of PVR and 26.9% prevalence of severe
PVR with mean retinal detachment duration of 58.4 ± 129.1
days [5]. Visual outcomes and the anatomical success of
surgery are worse for RD that is complicated by PVR and
may require twice as many resources to care for as those
cases of RD without PVR [6]. Here we review inﬂammatory
and other mechanisms involved in the pathogenesis of PVR,
we highlight important clinical trials, and we discuss how
ﬁndings at the bench have the potential to be translated to
the bedside.
2. The Macrophage Hypothesis for
Development of PVR
Some of the hypotheses regarding the pathogenesis of PVR
havefocusedontheroleofmacrophages[7–9].Inoneexper-
iment, rabbits were injected intravitreally with cells obtained
from their peritoneal cavity, consisting of 85% macrophages,
10% lymphocytes, a few neutrophils, and less than 1% ery-
throcytes [7]. One week after injection, intravitreal strands
had developed containing macrophages and ﬁbroblasts, with
massive epiretinal membranes developing between 4 to 9
weeks after injection in 17 of 24 eyes, posterior vitreous
separation in 16 of 24 eyes, and retinal detachment in 15 of
24 eyes. The researchers suggested that macrophage-derived
enzymesproducedchangesinthestructureofthevitreousby2 Mediators of Inﬂammation
proteolysis of matrix proteins and also that the development
of ﬁbrotic membranes was due to the synthesis of ﬁbroblast
growth factor by the macrophages, but not due to cellular
transdiﬀerentiation of macrophages into ﬁbroblast-like cells
[7]. Immunohistochemical analysis of surgical specimens of
patients with post-traumatic PVR indicated the presence
of macrophages and transferrin in periretinal membranes
[8]. It was suggested that the secretion of PDGF by
macrophages was central to the pathophysiology of PVR in
these specimens, since PDGF increases the density of the
cell surface receptor for transferrin [8, 10]. This hypothesis
is also supported by the development of PVR-models in
rabbits and rats in which injected macrophages acquire
ﬁbroblastic characteristics and contribute to the formation
of ﬁbrocellular membranes [9, 11]. Macrophages (CD68-
positive) were intravitreally injected into rats’ eyes and by
day 7, the majority of the rats (29/32) had white proliferative
membranes attached to their retina [11]. This was followed
by the development of neoformative membranes by day 14,
but the rats did not develop complete retinal detachment;
20 control rats that received PBS injection did not have any
proliferation or membrane formation. Furthermore, by day
28 a dense ﬁbrous connective tissue had formed that on
histology had a multilayer of ﬁbroblast-like cells which on
immunohistochemical analysis stained positive for vimentin
(marker for mesenchymal cells), but not cytokeratin (marker
of epithelial cells) or CD68 (marker of macrophages),
suggesting the primary cells of the PVR membranes were
ﬁbroblasts [11]. Injected macrophages retained a round
shape and CD68 on day 3, but on day 28 had developed
a spindle shape with staining of vimentin and absence
of CD68; the macrophages had acquired a ﬁbroblast-like
phenotype and contributed to the ﬁbrocellular membranes
directly [11]. It is likely that the role of macrophages in the
pathogenesis of PVR is multifactorial and involves a com-
bination of macrophage-secreted factors including enzymes
andgrowthfactors(e.g.,PDGF)andalsotransdiﬀerentiation
of macrophages into ﬁbroblast-like cells.
3.Injectionof Cellsintothe Vitreousas
a Model of PVR
InearlymodelsofPVR,apieceofdermaltissuewasdelivered
to the vitreous of rabbit eyes through a small cauterized
hole in the pars plana; growth of this tissue ensued, with
the development of vitreous strands between the tissue and
the retina, and ultimately retinal detachment in the majority
of cases [12]. This was followed by experiments in which
ﬁbroblasts were intravitreally injected into rabbits [13–15].
Autotransplanted, cultured skin ﬁbroblasts injected intrav-
itreally resulted in vitreous strands, preretinal pucker, and
traction detachment in 32 of 51 eyes [13]. In another rabbit
model, gas compression was used to simulate vitrectomy
and followed a week later by injection of autologous tissue-
cultured ﬁbroblasts; by post-op day 28, 10 of 10 eyes injected
with 50,000 ﬁbroblasts had developed transvitreal strands
and severe retinal detachment [14]. Meanwhile, in eyes
injected with 25,000 ﬁbroblasts, 7 of 11 showed transvit-
real strands, and 10 of 11 developed retinal detachment
[14]. In the epiretinal membranes of patients undergoing
vitreoretinal surgery for retinal detachment complicated by
PVR, all 16 samples contained myoﬁbroblasts expressing the
contractile protein α-smooth muscle actin [16]. In vitro, the
addition of bovine vitreous to cultures of RPE cells and
ﬁbroblasts stimulated the proliferation of these two cell types
[17]. Furthermore, pathologic vitreous from patients with
PVR stimulated contraction of cultured ﬁbroblasts in vitro
[18]. In rats, intravitreal injection of rat RPE (RPE-J) cells
and platelet-rich plasma resulted in proliferative membranes
and retinal detachment by post-injection day 28 [19].
Immunohistochemical analysis of membranes at days 14
and 28 revealed RPE cells expressing cytokeratin-18, glial
cells expressing GFAP, ﬁbroblasts expressing vimentin, and
ED-1 positive macrophages [19]. This evidence, along with
the macrophage model of PVR, suggests that it may be the
introduction of cells into the vitreous that triggers processes
leading to PVR, rather than the particular cell injected.
4.The Growth Factor and Cytokine Hypothesis
for Development of PVR
In the proposed growth factor and cytokine model for
the development of PVR, a break in the retina, such as
that occurring in RRD, creates an opening for vitreous to
come into contact with intraretinal cells and retinal pigment
epithelial (RPE) cells. Vitreal growth factors and cytokines,
now with access to these cells, promote an environment
of cell migration, proliferation, survival, and formation of
extracellular matrix proteins (Figure 1)[ 20]. As these struc-
tures form, they may physically attach to the retina, contract,
and cause retinal tears. Support for this hypothesis stems
from the presence of many growth factors and cytokines in
the pathological vitreous or epiretinal membrane, including
platelet-derived growth factor (PDGF) isoforms [21, 22],
hepatocyte growth factor (HGF) [22, 23], vascular endothe-
lial growth factor (VEGF) [24], epidermal growth factor
(EGF) [25], pigment epithelium-derived factor (PEDF) [26],
transforming growth factor β (TGFβ)[ 27, 28], tumor
necrosis factor α (TNFα)[ 29, 30], TNFβ [29], granulocyte
colony-stimulating factor (G-CSF) [29], ﬁbroblast growth
factors (FGF) [29, 31], basic ﬁbroblast growth factor (bFGF)
[32], insulin [25], insulin-like growth factor-1 (IGF-1) [33],
connective tissue growth factor (CTGF) [22, 23], glutamine
synthetase [32], interleukin 1 (IL-1) [34], IL-6 [29, 31], IL-8
[29, 35], IL-10 [29], interferon γ (IFNγ)[ 28, 29], monocyte
chemotactic protein [35, 36], macrophage-colony stimulat-
ing factor [35], granulocyte colony-stimulating factor (G-
CSF) [29], chemokine ligand 2 (CCL2) [29], CCL3 [29],
CCL4 [29], CCL5 [29], and protein [31].
5. Tumor Necrosis Factor Alpha as
aP r o m o t e ro fP V R
T u m o rn e c r o s i sf a c t o r( T N F ) α is a cytokine that promotes
inﬂammation, in part, by activating endothelial cells to
display leukocyte adhesion molecules such as E-selectin,
intercellular adhesion molecule-1, and vascular cell adhesionMediators of Inﬂammation 3
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Figure 1:IndirectactivationofPDGFRαbynon-PDGFstriggerstheeventsleadingtoproliferativevitreoretinopathy(PVR).Aretinaltearor
detachment(a)createsanopeningviawhichvitrealgrowthfactorsandcytokinesinteractwithintraretinalcellsandretinalpigmentepithelial
(RPE) cells. Vitreal VEGF-A competitively inhibits the binding of platelet-derived growth factors (PDGFs), including the predominant
isoformisolated inthevitreousof patientswith PVR,PDGF-C, tothereceptor PDGFR-α(b).Indoingso,VEGF-Apreventsdirectactivation
of PDGFRα by PDGFs. Direct activation of PDGFRα promotes rapid clearance of this receptor from the cell surface and subsequent
intracellular degradation; this rapid receptor cycling interferes (b) with the ability of non-PDGFs to activate the PDGFRα through an
indirect pathway as follows. Non-PDGFs, including basic ﬁbroblast growth factor (bFGF), epidermal growth factor (EGF), insulin, and
hepatocyte growth factor (HGF), activate their receptors, which results in an elevation of the level of intracellular reactive oxygen species
(ROS), which leads to activation of Src family kinases (SFKs) that promote phosphorylation and activation of PDGFRα (c). This pathway
of indirect activation results in persistent PDGFRα signaling and induces prolonged activation of phosphatidylinositol 3-kinase (PI3K)/Akt,
which phosphorylates murine double minute (Mdm2), which then suppresses p53 levels (c). This promotes an environment of cell survival,
proliferation, organization into a membrane, and subsequent membrane contraction, the processes intrinsic to PVR (d). Therefore, VEGF-
A inhibits physiological, direct activation of PDGFRα by PDGFs and favors pathological, persistent, indirect activation of the receptor by
non-PDGFs, triggering the events leading to PVR.
molecule-1 [37, 38]. TNFα was found in 22 of 26 epiretinal
membranes of patients with proliferative vitreoretinopathy,
with positive TNFα staining both intracellularly and in
the extracellular matrix [39]. TNFα is associated with the
production and secretion of the receptors sTNF-RI and
sTNF-RII, which are found on the majority of nucleated
cells; after activation by TNFα, these receptors are cleaved
by metalloproteinases [40] and found in the soluble form in
serum[41].sTNF-RIandsTNF-RIIarethoughttoneutralize
theinﬂammatoryeﬀectsofTNFαinvitroandinvivoandcan
be used clinically as markers of disease activity [42, 43]. The
levels of sTNF-RI and sTNF-RII were signiﬁcantly higher
(P<0.0003) in the vitreous of patients with PVR (244–
4290 and 128–4429pg/mL, resp.) compared to cadaveric
controls (101–836 and 96–551pg/mL, resp.) [44]. Groups in
the aforementioned study were not matched for age; another
study suggests that sTNF-RI and sTNF-RII are signiﬁcantly
increased in the serum of healthy older people (mean
71 years) and centenarians compared to younger, healthy
controls (mean 27.9 years) [45]. Genetic analysis of blood
samplesfrom138patientswithpost-rhegmatogenousretinal
detachment PVR demonstrated a signiﬁcant association
(P = 0.0283) with the nonsynonymous, single nucleotide
polymorphism (SNP) rs2229094(T→C) compared to con-
trols [46]. This is a SNP in the lymphotoxin alpha gene at
the tumor necrosis factor locus (6p21.3), which encodes a
cysteine to arginine change—from a neutral, hydrophobic
amino acid toa hydrophilic, positively chargedamino acid—
andmayhaveaneﬀectonproteintopologyoritsinteractions
[46]. Future studies on protein function may further eluci-
date the role of this SNP at the TNFα locus in PVR.
6. PDGFRs AreInvolvedin
the Pathogenesis of PVR
PDGF is an important link in the cell-cell interactions
of retinal cells and functions as a trophic factor during
the development of the retina [47, 48]. PDGFR has been
identiﬁed on the cell membranes of RPE cells, retinal glial
cells, and ﬁbroblasts, some of the cell types involved in PVR
[49, 50]. PDGF and activated PDGFR have been noted in the
epiretinal membranes, RPE, and glial cells of patients with
PVR, with high levels of PDGF in the vitreous closely associ-
ated with PVR (8/9 patients with PVR had detectable levels
of vitreal PDGF compared to 1/16 patients with a diﬀerent
retinal disease requiring surgery/vitrectomy) [51, 52]. Only4 Mediators of Inﬂammation
the PDGF-C isoform was isolated, which is produced mainly
by the protease plasmin [53]. This ﬁnding was corroborated
by a high level of PDGF-C in the vitreous of rabbit models
of PVR induced by ﬁbroblast injection [52, 54]. Additionally,
in experimental models, cells that lacked the PDGFR gene
had a low potential for PVR and reexpressing the wild
type PDGFR in these cells greatly increased the potential
for PVR [21, 50]. Inhibition of PDGFRs decreased cellular
PVR potential [55, 56]. Of the three diﬀerent PDGFRs: cells
expressing PDGFRα induce PVR much more eﬀectively than
cells expressing PDGFRβ in rabbits, and cells expressing
the heterodimer PDGFRαβ had intermediate potency in
inducing PVR [21]. This is supported clinically by analysis of
human specimens demonstrating that a greater percentage
of PDGFRα is activated [51]. In addition, PDGF-C, the
predominant PDGF isoform isolated in the vitreous of
patientswithPVR,activatesPDGFRαandPDGFRαβ butnot
PDGFRβ [52, 57].
7. IndirectActivation of PDGFR by
Non-PDGFs Triggersthe EventsLeadingto
ExperimentalPVR
Non-PDGFs can also activate PDGFRα; for example, bFGF,
EGF, insulin, and HGF induce tyrosine phosphorylation
of PDGFRα [25]. Non-PDGFs activated both full-length
PDGFRα and mutant receptors that lacked the extracellular
domain to a comparable extent, through the following
pathway: non-PDGFs activate their receptors, resulting in
an increase of intracellular reactive oxygen species (ROS),
then activation of Src family kinases (SFK), which leads to
phosphorylation of PDGFRα (Figure 1)[ 58]. New evidence
suggests that this indirect pathway involving non-PDGFs as
agonists of PDGFRα is the primary pathway for activation
of this receptor and an important part of the pathogenesis
of PVR. VEGF-A prevents binding of PDGF to PDGFRα,
inhibiting the direct pathway of PDGFRα activation and
downstream extracellular signal-related kinase (Erk) acti-
vation [59]. Neutralizing VEGF-A by adding anti-VEGF-
A antibodies to the vitreous of rabbits with PVR resulted
in a signiﬁcant increase in the activation of PDGFRα;
VEGF-A inﬂuences the mechanism of PDGFRα activation,
inhibiting the direct pathway and creating an environment
favoring non-PDGFs to indirectly activate PDGFRα [59].
While direct activation of PDGFRα results in rapid clearance
of the receptor from the surface and subsequent degrada-
tion, indirect activation by non-PDGFs promotes persistent
receptor signaling and induces prolonged activation of
phosphatidylinositol 3-kinase (PI3K)/Akt, which activates
murine double minute (Mdm2) to suppress p53 levels,
driving processes intrinsic to PVR-survival, proliferation,
and contraction (Figure 1)[ 59, 60].
8. Therapeutic Targeting of
the PDGF/PDGFRPathway
Attempts to prevent retinal detachment and PVR with anti-
bodies directed against PDGFs have yielded mixed results.
In photoreceptors of transgenic mice overexpressing PDGF-
B, the universal ligand for all three PDGF receptors,
intravitreal injection of an aptamer against PDGF-B was
protectiveagainstretinaldetachment[61].Inarabbit model,
antibodies against vitreal PDGFs inhibited them eﬀectively
but did not prevent PVR compared to controls (Table 1),
suggesting that the PDGFRs in this model were activated by
non-PDGFs [25]. Attempts were then made to inhibit the
indirect pathway of PDGFR activation, a pathogenesis that
involves an increase in ROS. In a comparison of cells null
for all PDGFRs and cells containing a truncated PDGFRα
that could only undergo indirect activation, both bFGF
(which increases ROS) and then separately rabbit vitreous,
c a u s e dt h ec e l l swi t ht r u n c a t e dP D G F R α to robustly contract
but did not cause contraction in control cells null for the
receptor. The experiment was then repeated in the presence
of N-acetyl-cysteine (NAC), an antioxidant that inhibits
ROS formation. At concentrations of 2.5mmol/L NAC and
above (NAC-induced toxicity began to occur at 20mmol/L),
contraction of the PDGFRα-cell lines was prevented, as
was the proliferative advantage of PDGFRα-containing cells
over control cells [62]. These ﬁndings were then applied in
vivo to PVR-model rabbits, where a vitreal concentration
of 10mmol/L of NAC was found to signiﬁcantly reduce
the PVR response compared to injection of buﬀer, with
suppressionpersisting3weekspost-NACinjection;whilethe
development of membranes occurred in most of the treated
rabbits, they did not progress to retinal detachment, and
analysis of PVR membranes revealed that control rabbits had
2.6timesthePDGFRαactivationcomparedtotreatedrabbits
(Table 1)[ 62]. NAC also prevented contraction of primary
RPE cells isolated from a human PVR membrane which was
subjected to the donor vitreous of ﬁve patients with PVR;
NAC may be used to suppress receptor activation and retinal
detachmentbutnottotargetpathologicalcells’viability[62].
9. Neutralizing a Subsetof Non-PDGFs and
Cytokinesto PreventPVR
Approaches with a cocktail of neutralizing reagents to target
multiplegrowthfactorsandcytokineshavealsobeenstudied.
One in vitro study assessed for the minimum possible
neutralizing set of antibodies that could be delivered to
prevent cellular contraction in the presence of pathologic
PVR vitreous. The minimum neutralizing set blocking PVR-
related signaling was found to be a cocktail of antibodies
that neutralized PDGFs, TGFα, EGF, HGF, FGF-2, TGFβ,I L -
8, and IGF-1 [63]. The rationale for neutralizing PDGFs,
despite evidence suggesting that the direct pathway of
PDGFRα activation plays only a minor role in PVR, was to
preempt against the possibility that inhibiting the indirect
pathway would then potentiate and increase the bioactivity
of the direct pathway. These ﬁndings were then applied in
vivo to rabbit PVR-models by treating twelve rabbits with
the minimum neutralizing cocktail and another twelve with
nonimmune IgG. Of the control rabbits, 8 (67%) developed
stage 3 PVR or higher with retinal detachments and the
other 4 (33%) developed stage 2 PVR. In contrast, noneMediators of Inﬂammation 5
T
a
b
l
e
1
:
O
u
t
c
o
m
e
s
o
f
t
h
e
r
a
p
e
u
t
i
c
a
g
e
n
t
s
u
s
e
d
i
n
a
n
i
m
a
l
s
t
o
p
r
e
v
e
n
t
p
r
o
l
i
f
e
r
a
t
i
v
e
v
i
t
r
e
o
r
e
t
i
n
o
p
a
t
h
y
(
P
V
R
)
.
A
g
e
n
t
(
s
)
D
o
s
e
a
n
d
t
a
r
g
e
t
I
n
v
i
v
o
m
o
d
e
l
T
r
e
a
t
m
e
n
t
g
r
o
u
p
s
O
u
t
c
o
m
e
s
R
e
f
.
A
R
C
1
2
6
,
A
R
C
1
2
7
,
A
R
C
1
2
8
2
0
μ
g
,
a
p
t
a
m
e
r
s
a
g
a
i
n
s
t
P
D
G
F
-
B
R
h
o
/
P
D
G
F
B
t
r
a
n
s
g
e
n
i
c
m
i
c
e
t
r
e
a
t
e
d
o
n
P
7
,
s
a
c
r
i
ﬁ
c
e
d
P
1
2
I
n
t
r
a
v
i
t
r
e
a
l
i
n
j
.
o
n
P
7
:
P
B
S
O
D
;
A
R
C
1
2
6
,
A
R
C
-
1
2
7
,
A
R
C
1
2
8
O
S
P
B
S
:
m
e
a
n
a
r
e
a
o
f
G
S
A
+
c
e
l
l
s
1
.
8
2
m
m
2
,
1
1
/
1
9
t
o
t
R
D
,
4
/
1
9
p
R
D
,
7
9
%
R
D
A
R
C
1
2
6
:
m
e
a
n
a
r
e
a
o
f
G
S
A
+
c
e
l
l
s
0
.
7
9
m
m
2
(
P
=
0
.
0
0
0
3
∗
)
,
0
t
o
t
R
D
,
1
/
6
p
R
D
,
1
7
%
R
D
A
R
C
1
2
7
:
m
e
a
n
a
r
e
a
o
f
G
S
A
+
c
e
l
l
s
0
.
5
5
m
m
2
(
P
=
0
.
0
0
0
1
∗
)
,
0
/
7
t
o
t
R
D
a
n
d
p
R
D
,
0
%
R
D
A
R
C
1
2
8
:
m
e
a
n
a
r
e
a
o
f
G
S
A
+
c
e
l
l
s
2
.
0
0
m
m
2
(
P
>
0
.
0
5
)
,
3
/
6
t
o
t
R
D
,
2
/
6
p
R
D
,
8
3
%
R
D
[
6
1
]
(
a
)
M
o
u
s
e
m
A
b
I
g
G
1
H
H
1
-
5
7
;
(
b
)
T
r
a
p
P
D
G
F
R
α
-
F
c
5
(
a
)
2
0
0
μ
g
,
i
n
h
i
b
i
t
s
P
D
G
F
-
C
(
b
)
3
8
6
μ
g
,
i
n
h
i
b
i
t
s
a
l
l
P
D
G
F
i
s
o
f
o
r
m
s
R
a
b
b
i
t
s
w
i
t
h
O
D
P
V
R
-
i
n
d
u
c
e
d
b
y
i
n
j
e
c
t
i
o
n
o
f
P
R
P
a
n
d
ﬁ
b
r
o
b
l
a
s
t
s
I
n
t
r
a
v
i
t
r
e
a
l
i
n
j
.
o
n
d
a
y
0
:
c
o
n
t
r
o
l
(
n
=
8
)
v
e
r
s
u
s
(
a
)
m
A
b
I
g
G
1
H
H
1
-
5
7
(
n
=
9
)
a
n
d
(
b
)
T
r
a
p
(
n
=
1
3
)
C
o
n
t
r
o
l
:
1
S
t
a
g
e
1
,
2
S
2
,
4
S
3
,
1
S
4
(
d
a
y
3
)
;
1
S
t
a
g
e
2
,
2
S
3
,
5
S
4
(
d
5
)
;
1
S
t
a
g
e
2
,
1
S
3
,
6
S
4
(
d
7
)
(
a
)
H
H
1
-
5
7
:
2
S
1
,
2
S
2
,
4
S
3
,
1
S
4
(
d
3
,
P
=
0
.
2
2
9
)
;
2
S
2
,
4
S
3
,
3
S
4
(
d
5
,
P
=
0
.
1
0
8
)
;
2
S
2
,
3
S
3
,
3
S
4
,
1
S
5
(
d
7
,
P
=
0
.
4
0
6
)
(
b
)
T
r
a
p
:
1
S
0
,
6
S
1
,
4
S
2
,
1
S
3
,
1
S
4
(
d
3
,
P
=
0
.
0
4
1
∗
)
;
3
S
1
,
3
S
2
,
4
S
3
,
3
S
4
(
d
5
,
P
=
0
.
0
6
3
)
;
4
S
1
,
2
S
2
,
3
S
3
,
4
S
4
(
d
7
,
P
=
0
.
0
5
8
)
[
2
5
]
N
-
a
c
e
t
y
l
-
c
y
s
t
e
i
n
e
(
N
A
C
)
1
0
m
m
o
l
/
L
,
r
e
d
u
c
e
s
R
O
S
l
e
v
e
l
s
R
a
b
b
i
t
s
w
i
t
h
O
D
P
V
R
-
i
n
d
u
c
e
d
b
y
i
n
j
e
c
t
i
o
n
o
f
P
R
P
a
n
d
ﬁ
b
r
o
b
l
a
s
t
s
I
n
t
r
a
v
i
t
r
e
a
l
i
n
j
.
o
n
d
a
y
s
0
,
2
,
4
,
a
n
d
7
:
c
o
n
t
r
o
l
(
n
=
1
0
)
v
e
r
s
u
s
N
A
C
(
n
=
1
0
)
C
o
n
t
r
o
l
:
2
S
t
a
g
e
0
,
8
S
1
(
d
1
)
;
1
S
0
,
7
S
1
,
2
S
2
(
d
3
)
;
8
S
1
,
1
S
2
,
1
S
4
(
d
5
)
;
5
S
1
,
2
S
2
,
2
S
3
,
1
S
4
(
d
7
)
;
S
1
,
3
S
2
,
2
S
3
,
1
S
4
,
1
S
5
(
d
1
4
)
;
4
S
1
,
2
S
2
,
1
S
3
,
1
S
4
,
2
S
5
(
d
2
1
)
;
3
S
1
,
3
S
2
,
1
S
4
,
3
S
5
(
d
2
8
)
;
2
.
6
x
↑
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
o
f
P
D
G
F
R
i
n
m
e
m
b
r
a
n
e
s
o
f
c
o
n
t
r
o
l
c
o
m
p
a
r
e
d
t
o
N
A
C
N
A
C
:
8
S
0
,
2
S
1
(
d
1
,
P
=
0
.
0
2
3
2
∗
)
;
9
S
0
,
1
S
1
(
d
3
,
P
=
0
.
0
0
1
1
∗
)
;
9
S
0
,
1
S
1
(
d
5
P
=
0
.
0
0
0
7
∗
)
;
7
S
0
,
3
S
1
(
d
7
,
P
=
0
.
0
0
1
5
∗
)
;
4
S
0
,
6
S
1
(
d
1
4
,
P
<
0
.
0
0
1
1
∗
)
;
3
S
0
,
5
S
1
,
2
S
2
(
d
2
1
,
P
<
0
.
0
3
2
∗
)
;
3
S
0
,
4
S
1
,
3
S
2
(
d
2
8
,
P
<
0
.
0
1
8
5
∗
)
;
n
o
p
r
o
g
r
e
s
s
i
o
n
t
o
R
D
[
6
2
]
M
i
n
i
m
u
m
n
e
u
t
r
a
l
i
z
i
n
g
a
n
t
i
b
o
d
y
s
e
t
(
M
N
A
S
)
A
n
t
i
b
o
d
y
s
e
t
a
g
a
i
n
s
t
P
D
G
F
s
,
T
G
F
α
,
E
G
F
,
H
G
F
,
F
G
F
-
2
,
T
G
F
β
,
I
L
-
8
,
a
n
d
I
G
F
-
1
R
a
b
b
i
t
s
w
i
t
h
O
D
P
V
R
-
i
n
d
u
c
e
d
b
y
i
n
j
e
c
t
i
o
n
o
f
P
R
P
a
n
d
ﬁ
b
r
o
b
l
a
s
t
s
I
n
t
r
a
v
i
t
r
e
a
l
i
n
j
.
o
n
d
a
y
0
:
c
o
n
t
r
o
l
(
n
=
1
2
)
v
e
r
s
u
s
M
N
A
S
(
n
=
1
2
)
C
o
n
t
r
o
l
:
4
/
1
2
(
3
3
%
)
s
t
a
g
e
2
P
V
R
,
8
/
1
2
(
6
7
%
)
s
t
a
g
e
3
P
V
R
o
r
h
i
g
h
e
r
w
i
t
h
R
D
M
N
A
S
:
3
/
1
2
(
2
5
%
)
n
o
p
a
t
h
o
l
o
g
y
,
5
/
1
2
(
4
2
%
)
e
p
i
r
e
t
i
n
a
l
m
e
m
b
r
a
n
e
,
4
/
1
2
(
3
3
%
)
s
t
a
g
e
2
P
V
R
,
n
o
R
D
[
6
3
]
P
D
G
F
:
p
l
a
t
e
l
e
t
-
d
e
r
i
v
e
d
g
r
o
w
t
h
f
a
c
t
o
r
.
A
R
C
1
2
8
:
n
o
n
f
u
n
c
t
i
o
n
a
l
v
e
r
s
i
o
n
o
f
A
R
C
1
2
7
.
P
7
:
p
o
s
t
n
a
t
a
l
d
a
y
7
.
P
1
2
:
p
o
s
t
n
a
t
a
l
d
a
y
1
2
.
i
n
j
.
:
i
n
j
e
c
t
i
o
n
.
P
B
S
:
p
h
o
s
p
h
a
t
e
-
b
u
ﬀ
e
r
e
d
s
a
l
i
n
e
.
O
D
:
r
i
g
h
t
e
y
e
.
O
S
:
l
e
f
t
e
y
e
.
G
S
A
+
c
e
l
l
s
:
e
c
t
o
p
i
c
c
e
l
l
s
i
n
t
h
e
i
n
n
e
r
r
e
t
i
n
a
s
t
a
i
n
i
n
g
p
o
s
i
t
i
v
e
f
o
r
G
r
i
ﬀ
o
n
i
a
s
i
m
p
l
i
c
i
f
o
l
i
a
l
e
c
t
i
n
.
t
o
t
R
D
:
t
o
t
a
l
,
p
R
D
:
p
a
r
t
i
a
l
,
R
D
:
r
e
t
i
n
a
l
d
e
t
a
c
h
m
e
n
t
.
∗
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
ﬁ
c
a
n
t
d
i
ﬀ
e
r
e
n
c
e
c
o
m
p
a
r
e
d
t
o
c
o
n
t
r
o
l
.
m
A
b
:
m
o
n
o
c
l
o
n
a
l
a
n
t
i
b
o
d
y
.
P
D
G
F
R
:
p
l
a
t
e
l
e
t
-
d
e
r
i
v
e
d
g
r
o
w
t
h
f
a
c
t
o
r
r
e
c
e
p
t
o
r
.
P
R
P
:
p
l
a
t
e
l
e
t
-
r
i
c
h
p
l
a
s
m
a
.
#
S
0
–
#
S
5
:
n
u
m
b
e
r
o
f
c
a
s
e
s
o
b
s
e
r
v
e
d
a
t
a
g
i
v
e
n
F
a
s
t
e
n
b
e
r
g
S
t
a
g
e
o
f
P
V
R
0
–
5
.
d
:
d
a
y
.
R
O
S
:
r
e
a
c
t
i
v
e
o
x
y
g
e
n
s
p
e
c
i
e
s
.
T
G
F
α
:
t
r
a
n
s
f
o
r
m
i
n
g
g
r
o
w
t
h
f
a
c
t
o
r
α
.
E
G
F
:
e
p
i
d
e
r
m
a
l
g
r
o
w
t
h
f
a
c
t
o
r
.
H
G
F
:
h
e
p
a
t
o
c
y
t
e
g
r
o
w
t
h
f
a
c
t
o
r
.
F
G
F
-
2
:
ﬁ
b
r
o
b
l
a
s
t
g
r
o
w
t
h
f
a
c
t
o
r
2
.
T
G
F
β
:
t
r
a
n
s
f
o
r
m
i
n
g
g
r
o
w
t
h
f
a
c
t
o
r
β
.
I
L
-
8
:
i
n
t
e
r
l
e
u
k
i
n
8
.
I
G
F
-
1
:
i
n
s
u
l
i
n
-
l
i
k
e
g
r
o
w
t
h
f
a
c
t
o
r
-
1
.
R
e
f
:
R
e
f
e
r
e
n
c
e
n
u
m
b
e
r
.6 Mediators of Inﬂammation
of the treated rabbits developed retinal detachment, with 3
(25%)havingnopathology,5(42%)developinganepiretinal
membrane, and 4 (33%) developing stage 2 PVR (Table 1)
[63]. Furthermore, treated eyes did not develop vitreal or
anterior chamber white cells, and the histology of one of
these treated rabbits revealed no retinal damage compared
to histology of the noninjected eye of the same rabbit [63].
10. 5-Fluorouracil(5-FU) and
Low-Molecular-WeightHeparin(LMWH):
ClinicalTrials
5-Fluorouracil(5-FU)isanantimetabolitethatinhibitsDNA
synthesis and ﬁbroblast proliferation [64]. Low-molecular-
weight heparin (LMWH) is an anticoagulant that binds
ﬁbronectin, bFGF, PDGF, and other growth factors [65].
Animal studies have found some eﬃcacy of 5-FU for the
treatment of vitreoretinal scarring [66, 67], but results in
human clinical trials have been mixed (Table 2)[ 68–70].
In one prospective, randomized, double-masked, placebo-
controlled trial, 174 high-risk patients were randomized to
receive 5-FU and LMWH (n = 87) versus placebo (n =
87) after primary vitrectomy for rhegmatogenous retinal
detachment [68]. The study reports a signiﬁcantly (P =
0.02) lower incidence of postoperative PVR in the 5-FU and
LMWH therapy group (11/87, 12.6%) compared to placebo
(23/87, 26.4%). In the treatment group, 19.5% (17/87) of
patients required more than one operation with 52.9%
(9/17) due to PVR compared to 25.3% (22/87) of patients
in the placebo group requiring reoperation with 72.7%
(16/22) due to PVR. There was no signiﬁcant diﬀerence in
visual acuity (VA) outcomes in the two groups although
patients with postoperative PVR had worse VA, nor were
there signiﬁcant diﬀerences in the complication rates of the
two groups [68]. In another randomized, controlled trial of
5-FU and LMWH in patients with established anterior or
posterior grade C PVR, patients were randomized to receive
a perioperative infusion with or without 200μg/mL of 5-
FU and 5IU/mL LMWH during vitreoretinal surgery and
silicone oil exchange [69]. The trial looked at the primary
outcome of posterior retinal reattachment after removal
of silicone oil without any reoperations at 6 months and
found no signiﬁcant diﬀerence (χ2 = 2.9, P = 0.59)
between the treatment group (56%, n = 73) and the placebo
group (51%, n = 84) [69] .T h e s et r i a l sw e r ef o l l o w e db y
a large, randomized, controlled trial of 5-FU and LMWH
versus placebo in 615 patients presenting with unselected
primary rhegmatogenous retinal detachment [70]. The main
outcome measure was retinal reattachment after primary
vitrectomy without any reoperations at 6 months with sec-
ondaryoutcomemeasuresincludingoccurrenceandgradeof
PVR and best-corrected visual acuity. Retinal reattachment
after primary vitrectomy was 82.3% in the combined 5-FU
and LMWH group (n = 327) and 86.8% in the placebo
group (n = 288; P = 0.12), with no statistically signiﬁcant
diﬀerence in development of PVR (7% in treatment group
compared to 4.9% in placebo group; P = 0.072), nor was
there a signiﬁcant diﬀerence in the median ﬁnal visual acuity
of the two groups [70]. Evidence for adjuvant therapy with
5-FU and LMWH for the prevention of PVR is mixed;
additional trials targeting prevention in patients with high
risk for PVR may provide greater insight [71].
11. Daunorubicinin the Treatment of PVR:
In Vitro,In Vivo,andClinicalTrials
Daunorubicin or daunomycin is an anthracycline that inhi-
bits cell proliferation and migration [72, 73]. Early use of
intraocular daunorubicin in vitro and in vivo in rabbits
determined that the concentration that caused a 50%
inhibition of colony-forming units was 700nM; the half-life
of daunomycin was determined to be 131 minutes in the
vitreous, conveying that critical concentrations of the drug
canbemaintainedformorethan4hoursafterinjection,with
safe elimination across the retina [73]. Daunorubicin used in
humans to reduce the failure rate of surgery for traumatic
proliferative vitreoretinopathy due to postoperative cellular
proliferation reported anatomic success in 14 out of 15
patients;daunorubicinwasdeliveredat7.5μg/mLoveraten-
minute period after vitrectomy and before silicone oil or
gas injection, with no reported toxicity to the optic nerve,
retina, lens, or cornea [74]. In a controlled clinical trial, 286
patients with advanced preoperative PVR were randomized
into standardized surgery with adjunctive daunorubicin or
surgery alone (Table 2)[ 75]. Outcomes included retinal
attachment with no additional vitreoretinal surgery to 6
months postop, number of and time to additional surgery
within 1 year of the ﬁrst operation, and best-corrected visual
acuity at 1 year postop. The trial demonstrated no signiﬁcant
diﬀerence (P = 0.07) in retinal attachment at 6 months post-
op between the two groups with the daunorubicin group
having 62.7% (89/142) attachment and 54.1% (73/135) in
the control group. In secondary outcomes, there was a
statistically signiﬁcant diﬀerence in the need for another
vitreoretinal operation within 1 year of the ﬁrst surgery (P =
0.005), with the daunorubicin group requiring fewer such
operations 34.5% (50/145) compared to the control group
46.1% (65/141); there was no diﬀerence in best-corrected
visual acuity [75]. There are a limited number of trials
studying the eﬃcacy of daunorubicin in prevention of PVR,
but it appears to be ineﬀective when used as a single agent.
12. Corticosteroids, 13-Cis-RetinoicAcid,
Cyclin-DependentKinases, and
Novel Compounds
Experiments in rabbits found that a single intravitreal injec-
tion of 1mg of triamcinolone acetonide eﬀectively inhibited
ﬁbroblast growth in a ﬁbroblast autotransplantation model,
reducing retinal detachment from 83.7% (36/43) to 34.1%
(15/44) as well as the rate of retinal neovascularization
from 72.1% (31/43) in controls to 18.2% (8/44) in treated
rabbits [76]. In a prospective clinical trial, however, a much
weaker response was seen; patients treated with systemic
steroidshada63.3%incidenceofretinalﬁbrosiscomparedto
75.4%ofpatientsgivenplacebofollowingretinaldetachmentMediators of Inﬂammation 7
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surgery [77]. 13-Cis-retinoic-acid (13cRA) has been found
to inhibit proliferation of RPE cells in vitro [78, 79]. A
randomized, controlled, clinical trial of 35 patients with
primary retinal detachment and PVR undergoing similar
surgery, assigned 16 patients to receive 10mg of oral 13cRA
twice daily for eight weeks postoperatively and the other 19
patients to the control group; the primary outcome measure
was retinal attachment at one-year followup (Table 2)[ 80].
At one-year followup, there was a statistically signiﬁcant
diﬀerence in retinal attachment (P = 0.047) between the
two groups, with 93.8% (15/16) of eyes in the 13cRA group
maintaining retinal attachment compared to 63.2% (12/19)
of eyes in the control group [80]. Other agents, including
thecyclin-dependentkinaseinhibitorroscovitineandanovel
anti-angiogenic compound IMS2186, have shown promise
in animal models for inhibiting the proliferation of retinal
pigment epithelial cells and ﬁbroblasts, respectively [81, 82].
13. Conclusions
Basic science and clinical studies continue to provide
growing insight into the pathophysiology of proliferative
vitreoretinopathy. In posttraumatic PVR, macrophages can
secretegrowthfactors(e.g.,PDGF)andcantransdiﬀerentiate
intoﬁbroblast-likecells,therebycontributingtovitreoretinal
membrane formation. In animal models, the injection of
cells into the vitreous, whether they are macrophages,
dermal tissue, ﬁbroblasts, or RPE-J cells, results in pathology
that mimics PVR. Tumor necrosis factor alpha, a pro-
inﬂammatory cytokine, has been identiﬁed in close associ-
ation with the membranes of patients with PVR, and genetic
analysis has identiﬁed a single nucleotide polymorphism at
the tumor necrosis factor locus that alters protein structure.
Inﬂammatory processes in the vitreous are accentuated by
the presence of growth factors, including PDGFs, HGF,
bFGF, and EGF, to name a few. These growth factors, and
especially the non-PDGFs, appear to activate PDGFRs on
the surface of RPE cells, retinal glial cells, and ﬁbroblasts,
leading to cell survival, proliferation, organization into a
membrane, and subsequent membrane contraction. Vitreal
VEGF-A appears to competitively inhibit the binding of
PDGFs to PDGFR-α. This promotes activation of PDGFR-
α by non-PDGFs through an indirect pathway that results
in persistent PDGFRα signaling—a pathway that leads to
prolonged suppression of p53 and triggers the events leading
to PVR. One key diﬀerence between animal models of PVR
and the disease as it occurs in humans is that in the majority
of animal models, PVR is induced by injection of cultured
ﬁbroblasts. Meanwhile, in humans, PVR may follow retinal
detachment or primary repair of rhegmatogenous retinal
detachment; the inﬂammatory process in humans is more
likely to involve cells local to the retina and vitreous rather
than cells introduced from outside the eye. While clinical
trials have thus far oﬀered mixed results in attempting to
prevent the pathogenesis of proliferative vitreoretinopathy,
experiments at the bench have provided novel strategies
in vitro and in animal models and oﬀer new avenues
clinicallyforfutureattemptstopreventthissight-threatening
disease. Clinical strategies to prevent PVR will probably
require a multimodal, combinatorial approach, such as ROS
inhibition and blocking the direct and indirect pathway of
PDGFRαactivation.Furthermore,parsplanavitrectomywill
remainacriticalcomponentofthetreatmentinrhegmatoge-
nous retinal detachment and PVR since residual vitreous is
a risk factor of PVR. Finally, attention should be given to
optimizing the correct dosing and administration of drugs,
since some of the past failures may be due to the manner and
timeofadministrationratherthanduetolackoftrueeﬃcacy
of the drugs tested.
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